PBRM1 and nonpapillary renal cell carcinoma: To test this, we co-treated PBRM1 mutant ccRCC cells with varying doses of PRT1419 and Everolimus (mTORCi) or Sunitinib (TKI) for 72h and assessed their combined effect on 3D cell proliferation.